CEO Casper von Koskull’s comments on the results: “2015 was a challenging year with exceptionally low interest rates, geopolitical tensions and market turmoil. Under these market conditions we are pleased to report an increase in the income level of 3% in local currencies2. We also delivered a reduction in costs to EUR 4.7bn, in line with our target, and credit quality improved during the year. Consequently, operating profit improved by 7%2. The Common Equity Tier 1 ratio improved 80 bps to 16.5%. The Board proposes a dividend per share of EUR 0.64 compared to the actual dividend of EUR 0.62 per share for 2014. The coming three years will be a transition period in which we will execute on our transformational change agenda in order to generate a truly digital bank. We will initiate certain key activities to manage the transition efficiently, which led to a restructuring charge of EUR 263m in the fourth quarter. Together with the investments in our core banking platform, the outcome of this transformational agenda will lead to a more efficient and straightforward structure and reduce administrative complexity to the benefit of our customers, employees and investors, and enable us to become truly “One Nordea”. Full year 2015 vs. Full year 2014 (Fourth quarter 2015 vs. Fourth quarter 2014)[1]: · Net interest income EUR 5,110m, -7%, in local currencies -4% (-8%, -6% in local currencies) · Total operating income EUR 9,964m excl. non-recurring items[2], +1%[2], in local currencies +3%[2] (-2%[2], unchanged in local currencies[2]) · Total operating expenses EUR 4,694m excluding non-recurring items[2], -4%[2], in local currencies -1%[2] (-2%[2], unchanged in local currencies[2]) · Profit before loan losses EUR 5,270m excluding non-recurring items[2], +5%[2], in local currencies +7%[2] (-2%[2], unchanged in local currencies) · Net loan losses EUR 479m, -10%, -8% in local currencies (+10%, +12% in local currencies) · Operating profit EUR 4,791m excluding non-recurring items[2], +7%[2], in local currencies +9%[2] (-4%[2], in local currencies -2%[2]) · Common equity tier 1 capital ratio 16.5%, up from 15.7% · Cost/income ratio down to 47.1%[2] from 49.3%[2] (up 0.2 %-points from 48.9%[2]) · Loan loss ratio of 14 basis points, down from 15 basis points (up 2 basis points to 17 basis points) · Return on equity 12.3%[2], up from 11.5%[2] (down 0.3 %-points to 11.5%) · Diluted EPS (total operations) EUR 0.91 vs. EUR 0.83 (EUR 0.21 vs. EUR 0.22) · Proposed dividend per share of EUR 0.64 vs. actual dividend per share of EUR 0.62 for 2014 Exchange rates used for Q4 2015 for income statement items are for DKK 7.46, NOK 8.94 and SEK 9.35 [1] Key figures for continuing operations, following the divestment of the Polish banking, financing and life insurance operations. [2] Excluding non-recurring items (Q2 2014: restructuring charge of EUR 190m, Q3 2014: gain from the divestment of Nets EUR 378m and impairment of intangible assets EUR 344m, Q4 2015: gain from divestment of Nordea’s merchant acquiring business to Nets of EUR 176m before tax and restructuring charge of EUR 263m) For further information: Casper von Koskull, President and Group CEO, +46 10 1571020 Torsten Hagen Jørgensen, Group COO, +45 5547 2200 Rodney Alfvén, Head of Investor Relations, +46 72 235 05 15 Claus Christensen, Head of Group Communications, +45 25248993 Latest interim results (http://www.nordea.com/en/investor-relations/reports-and -presentations/latest-interim-results/index.html) The information provided in this press release is such that Nordea is required to disclose pursuant to the Swedish Financial Instruments Trading Act (1991:980) and/or the Swedish Securities Markets Act (2007:528).
Fourth Quarter and Full Year Results 2015 CEO Casper von
Top 10 Most Recent News Articles
BTQ Technologies Calls Investors for Key Quantum Update
You know what's stirring the pot over at BTQ Technologies? A shareholder call coming up soon, and boy, it's got 'eye-opening insights' written all over it. We're talkin' Q3 financial results and, likely, a smattering of future plans on the quantum front, folks. Diving into BTQ's Quantum Vision BTQ Technologies Corp. (NASDAQ: BTQ) isn't just another tech firm banging on...
Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion
Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...
Continue Reading
SmallRig Boosts Art-Driven Innovation in AI Era
The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...
Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure
Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...
Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus
Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...
Continue Reading
El Pollo Loco Faces Class Action Over Wage Practices
Alright, here's where things start sizzling—El Pollo Loco, the fast-food chicken chain whose name translates to 'The Crazy Chicken'—is in a legal pickle. The lawsuit hanging over their heads could spell a sticky situation for them and possibly ripple through the fast-food industry. The suit, filed by the steadfast firm Blumenthal Nordrehaug Bhowmik De Blouw LLP, has...
Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart
A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...
Continue Reading
Windward Bio Surges 68% in Nasdaq Debut
Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...
Continue Reading
ManuTech Center Set to Revolutionize Manufacturing Hub
Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...
Continue Reading
HiTHIUM Joins Cambridge to Boost Global Energy Storage
HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...
Continue ReadingTop 5 Most Recently Viewed Articles
Kimbell Royalty Partners Engages Investors at Key Conferences
Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...
Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park
A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....
Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options
EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...
Continue Reading
IonQ Shares: Insights Into Their Current Market Performance
Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...
Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth
Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...
Continue Reading